Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255043 | 0.87 | KDM4E (0.58) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL18255044 | 0.85 | KDM4E (0.57) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20474703 | 0.85 | ACACB (0.47) | KDM4ESMN1; SMN2ALDH1A1HTTOPRK1 | |
| SCHEMBL1708419 | 0.85 | PTPN11 (0.53) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL21679479 | 0.85 | GPR119 (0.48) | KDM4EALDH1A1MAPTCHRM4CYP2C19 | |
| SCHEMBL20386100 | 0.84 | KDM4E (0.56) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3664698 | 0.83 | KDM4E (0.50) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL20425004 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1MAPTCHRM4CYP2C19 | |
| SCHEMBL18255216 | 0.83 | KDM4E (0.66) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15415370 | 0.83 | KDM4E (0.54) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3573974-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2024-09-18 | — | — | EP | disclosed |
| US-11974997-B2 | RORgamma modulators and uses thereof | GENFIT (FR) | 2024-05-07 | — | — | US | disclosed |
| CN-117777099-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115996719-A | BRAF degradation agent | C4医药公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20220133716-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2022-05-05 | — | — | US | disclosed |
| US-20220133716-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2022-05-05 | — | — | US | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-11160801-B2 | RORgamma modulators and uses thereof | GENFIT (FR) | 2021-11-02 | — | — | US | disclosed |
| US-11160801-B2 | RORgamma modulators and uses thereof | GENFIT (FR) | 2021-11-02 | — | — | US | disclosed |
| WO-2018138356-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | disclosed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2231653-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | Biota Europe Ltd (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074812-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133716-A1 | RORGAMMA MODULATORS AND USES THEREOF | RORB, RORC, RORA | KDM4E 2240/4885SMN1; SMN2 4781/4885MEN1 3748/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | KDM4E 1258/4885SMN1; SMN2 2554/4885MEN1 1552/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | KDM4E 332/4885SMN1; SMN2 3020/4885MEN1 512/4885 |
| US-11974997-B2 | RORgamma modulators and uses thereof | RORB, RORC, RORA | KDM4E 2240/4885SMN1; SMN2 4781/4885MEN1 3748/4885 |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | NEK6, NEK1, TXK | KDM4E 3573/4885SMN1; SMN2 3360/4885MEN1 2077/4885 |
| US-11160801-B2 | RORgamma modulators and uses thereof | RORB, RORC, RORA | KDM4E 2240/4885SMN1; SMN2 4781/4885MEN1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.